Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for pharmaceutical industry professionals · Saturday, December 9, 2023 · 673,940,324 Articles · 3+ Million Readers

MedGenome to present its tumor microenvironment analysis results at the AACR Cancer Immunotherapy Conference in New York

The analysis compares the immune microenvironment of uveal melanoma and skin cutaneous melanoma

FOSTER CITY, CALIFORNIA, UNITED STATES, July 21, 2016 / -- MedGenome will be presenting its analysis comparing the immune microenvironment of uveal melanoma and skin cutaneous melanoma at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, September 25-28, 2016, New York.

The remarkable success of checkpoint control inhibitors in treating a variety of different cancers has necessitated a deeper assessment of the tumor and its microenvironment at the genetic and phenotypic level. Data from recent clinical trials has unequivocally established that the tumor microenvironment significantly impacts the efficacy of immune-oncology drugs.

The study, which compared the tumor microenvironments of uveal melanoma vs skin cutaneous melanoma, involved a gene expression signature-based approach to qualitatively and quantitatively assess the epithelial, stromal and immune content of tumors from RNA-seq data. The immune cell content of the tumors was further stratified to determine the infiltration pattern of nine different immune cell types in the tumor. These signatures were then applied singly, or in combination on the TCGA RNA-seq data from 33 cancers.

And the study results suggest that gene expression signatures can address a critical unmet need in the immune-oncology space, which is to create a framework for treating tumors that carry less mutation burden combined with poor T-cell infiltration. The results also propose that therapies targeting MDSC cells, or those that can shift the balance towards increased M1 content over M2 are likely to show efficacy in Uveal melanoma, which are unresponsive to checkpoint inhibitor antibodies.

About MedGenome

MedGenome ( is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. Its unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized health care. MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally. It is also a founding member of GenomeAsia 100K initiative to sequence 100,000 genomes in South, North and East Asia.

Our NGS lab in Foster City, California is ISO 15189 compliant, CLIA certified and CAP accredited.

Forward-looking Statements:

This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Hiranjith GH
email us here

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release